Living with Severe and Eosinophillic Asthma 2020 report

“Living with Severe and Eosinophillic Asthma” is a syndicated report which offers valuable insights into patient attitudes and behaviour.

We recognise pharma brands need access to unique patient insights if they are to develop effective products, treatments and relevant communications messages. Living with severe and eosinophillic asthma is designed to provide in-depth understanding of the disease patient journey, from diagnosis through treatment and ongoing management. The report unveils patients attitudes, needs and support required at key stages of the journey.

Gain an in-depth understanding of:

Diagnosis pathway of severe and eosinophillic asthma patients
Extent to which the condition impacts day-to-day activities
Degree of stress / anxiety associated with asthma
Symptoms that have the greatest impact on sufferers
Reasons for delay in treatment initiation
Level of satisfaction with current treatment and patient unmet needs
Awareness of new products

Methodologies

Living with Severe and Eosinophillic Asthma 2EU

Methodology	Quant: 30-minute online surveys with adult asthma patients Qual: 30-minute qualitative telephone interviews with adult asthma patients
Countries	France	Germany	Total
Total	59	59	118
Sample considerations	Patients screened based on whether they have diagnosis and/or confirmed characteristics of severe asthma (SA) or eosinophilic asthma (EA) Given the challenges of recruiting these patient groups, no restrictive criteria placed on gender or age Number of patients currently and/or previously using biologics: n=9 SA patients n=31 EA patients

Living with Severe and Eosinophillic Asthma US

Methodology	Quant: 30-minute online surveys with adult asthma patients Qual: 30-minute qualitative telephone interviews with adult asthma patients
Countries	USA
Total	105
Sample considerations	Patients screened based on whether they have diagnosis and/or confirmed characteristics of severe asthma (SA) or eosinophilic asthma (EA) Given the challenges of recruiting these patient groups, no restrictive criteria placed on gender or age Number of patients currently and/or previously using biologics: n=10 SA patients n=29 EA patients

Living with Severe and Eosinophillic Asthma Japan

Methodology	Quant: 30-minute online surveys with adult asthma patients
Countries	Japan
Total	59
Sample considerations	Patients screened based on whether they have diagnosis and/or confirmed characteristics of severe asthma (SA) or eosinophilic asthma (EA) Given the challenges of recruiting these patient groups, no restrictive criteria placed on gender or age Number of patients currently and/or previously using biologics: n=2 SA patients n=9 EA patients

Podcast

Listen to our Living With Chronic Illness podcast. The second series covers severe and eosinophillic asthma.

Listen Right Arrows

Return to Living With page

Request more information on Living With

Mariel Metcalfe

Director, Head of Living With

Mariel is the Head of Living With and has 18 years of pharmaceutical market research experience in a wide variety of qualitative and quantitative methodologies, including global tracker research and segmentation. She has worked in a variety of therapy areas including infectious, autoimmune, respiratory and metabolic diseases. Mariel has extensive experience in patient insights and is committed to bringing the patient voice to life. She has written multiple articles and hosts the podcast ‘Living with Chronic Illness’ which is designed to give a voice to patients suffering from chronic conditions.

mariel.metcalfe@researchpartnership.com